Kymera Therapeutics, Inc.

NasdaqGM:KYMR Stock Report

Market Cap: US$2.6b

Kymera Therapeutics Future Growth

Future criteria checks 1/6

Kymera Therapeutics's earnings are forecast to decline at 11.4% per annum while its annual revenue is expected to grow at 16.7% per year. EPS is expected to decline by 6.5% per annum. Return on equity is forecast to be -98.5% in 3 years.

Key information

-11.4%

Earnings growth rate

-6.5%

EPS growth rate

Biotechs earnings growth27.6%
Revenue growth rate16.7%
Future return on equity-98.5%
Analyst coverage

Good

Last updated19 Dec 2024

Recent future growth updates

Earnings Update: Kymera Therapeutics, Inc. (NASDAQ:KYMR) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts

Nov 04
Earnings Update: Kymera Therapeutics, Inc. (NASDAQ:KYMR) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts

Analysts Are Upgrading Kymera Therapeutics, Inc. (NASDAQ:KYMR) After Its Latest Results

Aug 11
Analysts Are Upgrading Kymera Therapeutics, Inc. (NASDAQ:KYMR) After Its Latest Results

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Released Earnings Last Week And Analysts Lifted Their Price Target To US$47.43

Feb 25
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Released Earnings Last Week And Analysts Lifted Their Price Target To US$47.43

Recent updates

Kymera: Protein Degradation Could Drive Dupixent-Like Value

Dec 07

Earnings Update: Kymera Therapeutics, Inc. (NASDAQ:KYMR) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts

Nov 04
Earnings Update: Kymera Therapeutics, Inc. (NASDAQ:KYMR) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts

Kymera's Protein Degradation Technology: A Promising Bet For Long-Term Biotech Investors

Oct 06

Analysts Are Upgrading Kymera Therapeutics, Inc. (NASDAQ:KYMR) After Its Latest Results

Aug 11
Analysts Are Upgrading Kymera Therapeutics, Inc. (NASDAQ:KYMR) After Its Latest Results

Kymera Therapeutics, Inc.'s (NASDAQ:KYMR) 27% Share Price Surge Not Quite Adding Up

Jul 14
Kymera Therapeutics, Inc.'s (NASDAQ:KYMR) 27% Share Price Surge Not Quite Adding Up

Shareholders Will Probably Hold Off On Increasing Kymera Therapeutics, Inc.'s (NASDAQ:KYMR) CEO Compensation For The Time Being

Jun 12
Shareholders Will Probably Hold Off On Increasing Kymera Therapeutics, Inc.'s (NASDAQ:KYMR) CEO Compensation For The Time Being

We Think Kymera Therapeutics (NASDAQ:KYMR) Can Easily Afford To Drive Business Growth

May 03
We Think Kymera Therapeutics (NASDAQ:KYMR) Can Easily Afford To Drive Business Growth

Kymera Therapeutics: Advancing Into Phase 2 With Partner Sanofi - I Still Have Faith

Mar 21

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Released Earnings Last Week And Analysts Lifted Their Price Target To US$47.43

Feb 25
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Released Earnings Last Week And Analysts Lifted Their Price Target To US$47.43

Optimistic Investors Push Kymera Therapeutics, Inc. (NASDAQ:KYMR) Shares Up 39% But Growth Is Lacking

Feb 17
Optimistic Investors Push Kymera Therapeutics, Inc. (NASDAQ:KYMR) Shares Up 39% But Growth Is Lacking

Kymera Therapeutics, Inc.'s (NASDAQ:KYMR) Shares Climb 33% But Its Business Is Yet to Catch Up

Dec 29
Kymera Therapeutics, Inc.'s (NASDAQ:KYMR) Shares Climb 33% But Its Business Is Yet to Catch Up

We Think Kymera Therapeutics (NASDAQ:KYMR) Needs To Drive Business Growth Carefully

Nov 06
We Think Kymera Therapeutics (NASDAQ:KYMR) Needs To Drive Business Growth Carefully

Industry Analysts Just Made A Substantial Upgrade To Their Kymera Therapeutics, Inc. (NASDAQ:KYMR) Revenue Forecasts

Aug 31
Industry Analysts Just Made A Substantial Upgrade To Their Kymera Therapeutics, Inc. (NASDAQ:KYMR) Revenue Forecasts

Here's Why We're Not Too Worried About Kymera Therapeutics' (NASDAQ:KYMR) Cash Burn Situation

Aug 04
Here's Why We're Not Too Worried About Kymera Therapeutics' (NASDAQ:KYMR) Cash Burn Situation

Kymera Therapeutics, Inc.'s (NASDAQ:KYMR) Share Price Not Quite Adding Up

May 21
Kymera Therapeutics, Inc.'s (NASDAQ:KYMR) Share Price Not Quite Adding Up

We're Hopeful That Kymera Therapeutics (NASDAQ:KYMR) Will Use Its Cash Wisely

Apr 16
We're Hopeful That Kymera Therapeutics (NASDAQ:KYMR) Will Use Its Cash Wisely

Companies Like Kymera Therapeutics (NASDAQ:KYMR) Are In A Position To Invest In Growth

Dec 28
Companies Like Kymera Therapeutics (NASDAQ:KYMR) Are In A Position To Invest In Growth

Earnings and Revenue Growth Forecasts

NasdaqGM:KYMR - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202662-304-209-23018
12/31/202569-264-246-16721
12/31/202454-210-221-17720
9/30/202488-167-148-125N/A
6/30/202489-158-138-106N/A
3/31/202479-155-136-98N/A
12/31/202379-147-137-103N/A
9/30/202347-167-174-150N/A
6/30/202352-158-169-153N/A
3/31/202347-159-163-157N/A
12/31/202247-155-156-153N/A
9/30/202246-154-155-152N/A
6/30/202257-139-157-155N/A
3/31/202264-124-148-146N/A
12/31/202173-100-131-129N/A
9/30/202170-79-113-111N/A
6/30/202165-585458N/A
3/31/202149-486977N/A
12/31/202034-557988N/A
9/30/202023-539097N/A
6/30/20209-57-52-47N/A
3/31/20206-52-17-15N/A
12/31/20193-411718N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: KYMR is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: KYMR is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: KYMR is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: KYMR's revenue (16.7% per year) is forecast to grow faster than the US market (9.1% per year).

High Growth Revenue: KYMR's revenue (16.7% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: KYMR is forecast to be unprofitable in 3 years.

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 20:05
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Kymera Therapeutics, Inc. is covered by 27 analysts. 21 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Zhiqiang ShuBerenberg
Etzer DaroutBMO Capital Markets Equity Research
Tazeen AhmadBofA Global Research